{"id":11349,"date":"2020-07-22T20:23:46","date_gmt":"2020-07-22T18:23:46","guid":{"rendered":"https:\/\/udic.es\/?p=11349"},"modified":"2020-07-23T10:59:15","modified_gmt":"2020-07-23T08:59:15","slug":"fda-approves-sublingual-apomorphine-in-off-periods","status":"publish","type":"post","link":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/","title":{"rendered":"FDA approves sublingual apomorphine in off periods"},"content":{"rendered":"<p>The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson&#8217;s disease  with motor fluctuations. We have led the clinical trial in Spain with this drug. Our patients are continuing to use it during the open label extension.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson&#8217;s disease with motor fluctuations. We have led the clinical trial in Spain with this drug. Our patients are continuing to use it during the open label extension.<\/p>\n","protected":false},"author":4,"featured_media":9251,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130,1],"tags":[],"class_list":["post-11349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-parkinson-en","category-uncategorised"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA approves sublingual apomorphine in off periods - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica<\/title>\n<meta name=\"description\" content=\"The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson&#039;s disease with motor fluctuations. We have led the clinical\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA approves sublingual apomorphine in off periods - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"og:description\" content=\"The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson&#039;s disease with motor fluctuations. We have led the clinical\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-22T18:23:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-07-23T08:59:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/udic.es\/wp-content\/uploads\/2020\/07\/th-2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"318\" \/>\n\t<meta property=\"og:image:height\" content=\"175\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"SUSANA ANDRADE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"SUSANA ANDRADE\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/\"},\"author\":{\"name\":\"SUSANA ANDRADE\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\"},\"headline\":\"FDA approves sublingual apomorphine in off periods\",\"datePublished\":\"2020-07-22T18:23:46+00:00\",\"dateModified\":\"2020-07-23T08:59:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/\"},\"wordCount\":49,\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"articleSection\":[\"Parkinson\",\"Uncategorised\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/\",\"url\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/\",\"name\":\"FDA approves sublingual apomorphine in off periods - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"isPartOf\":{\"@id\":\"https:\/\/udic.es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"datePublished\":\"2020-07-22T18:23:46+00:00\",\"dateModified\":\"2020-07-23T08:59:15+00:00\",\"description\":\"The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson's disease with motor fluctuations. We have led the clinical\",\"breadcrumb\":{\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#primaryimage\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png\",\"width\":815,\"height\":246,\"caption\":\"logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/udic.es\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA approves sublingual apomorphine in off periods\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udic.es\/#website\",\"url\":\"https:\/\/udic.es\/\",\"name\":\"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"description\":\"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica\",\"publisher\":{\"@id\":\"https:\/\/udic.es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udic.es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/udic.es\/#organization\",\"name\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\",\"url\":\"https:\/\/udic.es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"contentUrl\":\"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png\",\"width\":408,\"height\":123,\"caption\":\"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica\"},\"image\":{\"@id\":\"https:\/\/udic.es\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03\",\"name\":\"SUSANA ANDRADE\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/udic.es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g\",\"caption\":\"SUSANA ANDRADE\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA approves sublingual apomorphine in off periods - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson's disease with motor fluctuations. We have led the clinical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/","og_locale":"en_US","og_type":"article","og_title":"FDA approves sublingual apomorphine in off periods - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","og_description":"The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson's disease with motor fluctuations. We have led the clinical","og_url":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/","og_site_name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","article_publisher":"https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci%c3%b3-Cl%c3%adnica-447149502490430\/","article_published_time":"2020-07-22T18:23:46+00:00","article_modified_time":"2020-07-23T08:59:15+00:00","og_image":[{"width":318,"height":175,"url":"https:\/\/udic.es\/wp-content\/uploads\/2020\/07\/th-2.jpeg","type":"image\/jpeg"}],"author":"SUSANA ANDRADE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"SUSANA ANDRADE"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#article","isPartOf":{"@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/"},"author":{"name":"SUSANA ANDRADE","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03"},"headline":"FDA approves sublingual apomorphine in off periods","datePublished":"2020-07-22T18:23:46+00:00","dateModified":"2020-07-23T08:59:15+00:00","mainEntityOfPage":{"@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/"},"wordCount":49,"publisher":{"@id":"https:\/\/udic.es\/#organization"},"image":{"@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","articleSection":["Parkinson","Uncategorised"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/","url":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/","name":"FDA approves sublingual apomorphine in off periods - UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","isPartOf":{"@id":"https:\/\/udic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#primaryimage"},"image":{"@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#primaryimage"},"thumbnailUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","datePublished":"2020-07-22T18:23:46+00:00","dateModified":"2020-07-23T08:59:15+00:00","description":"The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson's disease with motor fluctuations. We have led the clinical","breadcrumb":{"@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#primaryimage","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/07\/logo.png","width":815,"height":246,"caption":"logo"},{"@type":"BreadcrumbList","@id":"https:\/\/udic.es\/en\/fda-approves-sublingual-apomorphine-in-off-periods\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/udic.es\/en\/"},{"@type":"ListItem","position":2,"name":"FDA approves sublingual apomorphine in off periods"}]},{"@type":"WebSite","@id":"https:\/\/udic.es\/#website","url":"https:\/\/udic.es\/","name":"UDIC Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","description":"Unitat D&#039;Investigaci\u00f3 Cl\u00ednica","publisher":{"@id":"https:\/\/udic.es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/udic.es\/#organization","name":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica","url":"https:\/\/udic.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/","url":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","contentUrl":"https:\/\/udic.es\/wp-content\/uploads\/2017\/08\/logo.png","width":408,"height":123,"caption":"UDIC Unitat D'Investigaci\u00f3 Cl\u00ednica"},"image":{"@id":"https:\/\/udic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/UDIC-Unitat-dInvestigaci\u00f3-Cl\u00ednica-447149502490430\/"]},{"@type":"Person","@id":"https:\/\/udic.es\/#\/schema\/person\/7b598050df55fbeadbf6cdc699c31c03","name":"SUSANA ANDRADE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/udic.es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ae155cf03dc49fd596e9750d3cfd63ee?s=96&d=mm&r=g","caption":"SUSANA ANDRADE"}}]}},"_links":{"self":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/11349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/comments?post=11349"}],"version-history":[{"count":2,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/11349\/revisions"}],"predecessor-version":[{"id":11356,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/posts\/11349\/revisions\/11356"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media\/9251"}],"wp:attachment":[{"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/media?parent=11349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/categories?post=11349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udic.es\/en\/wp-json\/wp\/v2\/tags?post=11349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}